Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.
New Jersey Medical School National Tuberculosis Center, 225 Warren St., P.O. Box 1709, Newark, NJ 07101-1709, USA. reichmlb@umdnj.edu
Lee B
LB
Reichman
Alfred
A
Lardizabal
Christopher H
CH
Hayden
D000818:Animals; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003365:Costs and Cost Analysis; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D004641:Emigration and Immigration; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D010349:Patient Compliance; D012293:Rifampin / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D013997:Time Factors; D014376:Tuberculosis / Q000188:drug therapy*; D014481:United States
D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin